Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 109

Sort by

Sort Order Select

Journal Articles

Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)

Blood (2019) 134 (Supplement_1): 1299.

https://doi.org/10.1182/blood-2019-130283

Published: 2019

Journal Articles

Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BiTE®-Mediated Cytotoxicity in Vitro

Veit Bücklein, MD, Michaela Scheurer, Bettina Brauchle, MSc, Roman Kischel, MD, Michael von Bergwelt, Karsten Spiekermann, MD, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 2632.

https://doi.org/10.1182/blood-2019-129057

Published: 2019

Journal Articles

Evaluating ROR1 As a Target in Childhood Leukemia

Paraskevi Diamanti, PhD, Bethan Kathleen Bailey, BSc, Obinna Ebere Iheanacho, MD, Amit C. Nathwani, MD PhD, Allison Blair, PhD

Blood (2019) 134 (Supplement_1): 2635.

https://doi.org/10.1182/blood-2019-126734

Published: 2019

Journal Articles

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

Pier Edoardo Rovatti, MD, Laura Zito, MSc, Eleonora Draghi, MSc, Monika Herrmann, PhD, Anetta Marcinek, MSc, Bettina Brauchle, MSc, Cesare Covino, MSc, Mattia Di Bono, MSc, Matteo Giovanni Carrabba, MD, Massimo Bernardi, MD, Karl-Peter Hopfner, PhD, Cristina Toffalori, PhD, Fabio Ciceri, MD, Marion Subklewe, MD, Luca Vago, MD PhD

Blood (2019) 134 (Supplement_1): 513.

https://doi.org/10.1182/blood-2019-126641

Published: 2019

Journal Articles

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

Shih-Feng Cho, MD PhD, Liang Lin, PhD, Lijie Xing, MD, Kenneth Wen, Tengteng Yu, MD PhD, Phillip A Hsieh, Yuyin Li, PhD, Nikhil C. Munshi, MD, Joachim Wahl, PhD, Katja Matthes, Kenneth C. Anderson, MD, Tara Chapman-Arvedson, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 135.

https://doi.org/10.1182/blood-2019-128528

Published: 2019

Journal Articles

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Deborah A. Katz, MD, Michael P. Chu, Kevin A. David, MD, Catherine Thieblemont, MD PhD, Nicholas J. Morley, Sharif S. Khan, Yuqi Chen, James Kalabus, Joan Morris, Abraham Anderson, Ariel A. Avilion, Eva González-Barca, MD PhD

Blood (2019) 134 (Supplement_1): 4077.

https://doi.org/10.1182/blood-2019-121708

Published: 2019

Journal Articles

CRISPR/Cas9-Mediated Protection of Normal Hematopoiesis Combined with the CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody AMG330 for Improved AML Therapy

Olivier Humbert, PhD, Mallory J Llewellyn, George S. Laszlo, PhD, Roland B. Walter, MD PhD MS, Hans-Peter Kiem, MD PhD

Blood (2019) 134 (Supplement_1): 4427.

https://doi.org/10.1182/blood-2019-129399

Published: 2019

Journal Articles

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Amber C. King, PharmD, BCOP, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3887.

https://doi.org/10.1182/blood-2019-128506

Published: 2019

Journal Articles

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity

Anilkumar Gopalakrishnapillai, PhD, Colin Correnti, PhD, Anne Kisielewski, BS, Allison Kaeding, MD, Soheil Meshinchi, MD PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 3925.

https://doi.org/10.1182/blood-2019-130941

Published: 2019

Journal Articles

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Hong Mu-Mosley, MD PhD, Lauren B Ostermann, Muharrem Muftuoglu, MD, Wendy Schober, Nalini B Patel, Abishek Vaidya, MS, Challice L. Bonifant, MD PhD, Stephen Gottschalk, MD, Mireya Paulina Velasquez, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3917.

https://doi.org/10.1182/blood-2019-125928

Published: 2019

Journal Articles

Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Guillaume Richard-Carpentier, MD, Hagop M. Kantarjian, MD, Nicholas J. Short, MD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Heather M Schroeder, Guillermo Garcia-Manero, MD, Guillermo Montalban Bravo, MD, Jorge E. Cortes, MD, Monica Kwari, BSN, Christopher Loiselle, BS, Rebecca Garris, MSc, Nicole Volter, RDC, Nitin Jain, MD, Marina Y Konopleva, MD PhD, Koichi Takahashi, MD, Koji Sasaki, MD, William G. Wierda, MD PhD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 3807.

https://doi.org/10.1182/blood-2019-129657

Published: 2019

Journal Articles

Inducible MyD88 Signaling Enhances the Anti-AML Activity of BiTE-Secreting ENG T-Cells

Abishek Vaidya, MS, Erin E Doherty, MD, Xiya Wu, Challice L. Bonifant, MD PhD, Stephen Gottschalk, MD, Mireya Paulina Velasquez, MD

Blood (2019) 134 (Supplement_1): 4441.

https://doi.org/10.1182/blood-2019-125395

Published: 2019

Journal Articles

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Amber C. King, PharmD, BCOP, Rachel Bolanos, PhD MPH, Kelly Velasco, PharmD, Huakang Tu, PhD, Faraz Zaman, MD, Mark B. Geyer, MD, Jae H. Park, MD

Blood (2019) 134 (Supplement_1): 5079.

https://doi.org/10.1182/blood-2019-122745

Published: 2019

Journal Articles

Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials

Zunairah Shah, MBBS, Mustafa Nadeem Malik, MD, Syeda Sabeeka Batool, MBBS, MD, Sravanthi Kotapati, MBBS, Aisha Akhtar, MBBS, Owais ur Rehman, MBBS, Marium Ghani, MBBS, Maryam Sadiq, MBBS, Arshia Akbar, MD, Aqsa Ashraf, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Hafiz Muhammad Fazeel, MBBS, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5567.

https://doi.org/10.1182/blood-2019-129652

Published: 2019

Journal Articles

Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review

Zunairah Shah, MBBS, Syeda Sabeeka Batool, MBBS, MD, Hafiz Muhammad Fazeel, MBBS, Mustafa Nadeem Malik, MD, Maryam Sadiq, MBBS, Syeda Fatima Hassan, MBBS, Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Nisma Javed, MBBS, Aqsa Ashraf, MD, Arafat Ali Ali Farooqui, MD, Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Marium Ghani, MBBS, Arshia Akbar, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5597.

https://doi.org/10.1182/blood-2019-131849

Published: 2019

Journal Articles

Blinatumomab and Venetoclax for Minimal Residual Disease Relapse in Acute Lymphoblastic Leukemia

Gregorio Campos-Cabrera, MD, Noe-Benjamin Vega-Tapia, MD, Virgina Campos-Cabrera, QFB EBC, Salvador Campos-Cabrera, MD, Jose-Luis Campos-Villagomez, MD, Esther Mendez-Garcia, MD

Blood (2019) 134 (Supplement_1): 5128.

https://doi.org/10.1182/blood-2019-127296

Published: 2019

Journal Articles

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Yukio Kobayashi, Iekuni Oh, MD PhD, Toshihiro Miyamoto, MD PhD, Won-Sik Lee, Hiroatsu Iida, MD PhD, Hironobu Minami, MD PhD, Yoshinobu Maeda, MD PhD, Jun Ho Jang, Sung-Soo Yoon, MD PhD, Su-Peng Yeh, MD, Qui Tran, Joan Morris, Janet L. Franklin, Ka-Wing Chong, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 5069.

https://doi.org/10.1182/blood-2019-124582

Published: 2019

Journal Articles

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Franco Locatelli, MD, Gerhard Zugmaier, Peter Bader, MD, Sima Jeha, MD, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, MD PhD, Rupert Handgretinger, MD, Benoit Brethon, MD, Claudia Rossig, Christiane Chen-Santel

Blood (2019) 134 (Supplement_1): 1294.

https://doi.org/10.1182/blood-2019-121615

Published: 2019

Journal Articles

Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct

Lea Pawlowsky, Bettina Brauchle, MSc, Maryam Kazerani Pasikhani, Ana Ogrinc Wagner, PhD, Veit Bücklein, MD, Felix S. Lichtenegger, MD, Roman Kischel, MD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Michael Andreeff, MD PhD, Naval G. Daver, MD, Michael von Bergwelt, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 1265.

https://doi.org/10.1182/blood-2019-122415

Published: 2019

Journal Articles

Redirecting T-Cells Against AML in a Multidimensional Targeting Space Using T-Cell Engaging Antibody Circuits (TEAC)

Eleanor Minogue, BSc, David Millar, PhD, Yan Chuan, PhD, Songfa Zhang, MD PhD, Korneel Grauwet, PhD, Mei Guo, Adam Langenbucher, Cyril H Benes, James Heather, PhD, Jeremy Minshull, PhD, Michael S. Lawrence, PhD, Rupa Narayan, David M. Langenau, PhD, Timothy A. Graubert, MD, Mark Cobbold

Blood (2019) 134 (Supplement_1): 2653.

https://doi.org/10.1182/blood-2019-127634

Published: 2019

NARROW

Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)

Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BiTE®-Mediated Cytotoxicity in Vitro

Evaluating ROR1 As a Target in Childhood Leukemia

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

CRISPR/Cas9-Mediated Protection of Normal Hematopoiesis Combined with the CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody AMG330 for Improved AML Therapy

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Inducible MyD88 Signaling Enhances the Anti-AML Activity of BiTE-Secreting ENG T-Cells

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials

Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review

Blinatumomab and Venetoclax for Minimal Residual Disease Relapse in Acute Lymphoblastic Leukemia

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct

Redirecting T-Cells Against AML in a Multidimensional Targeting Space Using T-Cell Engaging Antibody Circuits (TEAC)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only